A virtual reality (VR) sickness assessment method according to an embodiment includes receiving virtual reality content, and quantitatively evaluating virtual reality sickness for the received virtual reality content using a neural network based on a pre-trained neural mismatch model. The evaluating of the virtual reality sickness may include predicting an expected visual signal for an input visual signal of the virtual reality content based on the neural mismatch model, extracting a neural mismatch feature between the predicted expected visual signal based on the neural mismatch model and an input visual signal for a corresponding frame of the virtual reality content corresponding to the expected visual signal, and evaluating a level of the virtual reality sickness based on the neural mismatch model and the extracted neural mismatch feature.

A virtual reality (VR) sickness assessment method according to an embodiment includes receiving virtual reality content, and quantitatively evaluating virtual reality sickness for the received virtual reality content using a neural network based on a pre-trained neural mismatch model. The evaluating of the virtual reality sickness may include predicting an expected visual signal for an input visual signal of the virtual reality content based on the neural mismatch model, extracting a neural mismatch feature between the predicted expected visual signal based on the neural mismatch model and an input visual signal for a corresponding frame of the virtual reality content corresponding to the expected visual signal, and evaluating a level of the virtual reality sickness based on the neural mismatch model and the extracted neural mismatch feature.

An activity mat for kinesthetic learners to develop cognitive skills through several movement patterns, that has a lateral line running in a lateral direction and a longitudinal line running in a longitudinal direction, thereby dividing the activity mat into four square segments. Each one of the respective square segments has an attachment means provided and four detachable indicia provided on the plurality of respective segments through the four respective attachments means.

Personal care devices (or apparatuses) are described to deliver/activate a bioactive compound/botanical compound/biologically active molecule (including a regulatory protein/growth factor) or a mixture of bioactive compounds/botanical compounds/biologically active molecules (including regulatory proteins/growth factors) for growth and protection of hair or rejuvenation and protection of skin, which utilizes nanoencapsulation/nanoemulsion and/or activation/photoactivation. Such devices (or apparatuses) utilize a light low intensity module/x-ray and nanooptical elements/three-dimensionally (3-D) printed micro/nanostructures. Furthermore, the personal care devices (or apparatuses) can be enhanced with an artificial intelligence (AI) algorithm and/or augmented reality (AR) application (app).

Personal care devices (or apparatuses) are described to deliver/activate a bioactive compound/botanical compound/biologically active molecule (including a regulatory protein/growth factor) or a mixture of bioactive compounds/botanical compounds/biologically active molecules (including regulatory proteins/growth factors) for growth and protection of hair or rejuvenation and protection of skin, which utilizes nanoencapsulation/nanoemulsion and/or activation/photoactivation. Such devices (or apparatuses) utilize a light low intensity module/x-ray and nanooptical elements/three-dimensionally (3-D) printed micro/nanostructures. Furthermore, the personal care devices (or apparatuses) can be enhanced with an artificial intelligence (AI) algorithm and/or augmented reality (AR) application (app).

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

An education tool includes a sheet with a plurality of small pockets formed across a front face, and a rear pocket formed across a rear face. The sheet and the pockets are formed from a transparent material. The large rear pocket is configured so that an answer card can be inserted therein to show a series of answers frontwards, and a picture rearwards. The small pockets holding in use a plurality of question cards, their inner faces showing part of a larger picture, their outer faces showing a question. The question cards and answer card configured so that when all the question cards are inserted in the correct locations, the part pictures on their rear faces will mosaic to show substantially the same picture as on the rear of the answer card.

An education tool includes a sheet with a plurality of small pockets formed across a front face, and a rear pocket formed across a rear face. The sheet and the pockets are formed from a transparent material. The large rear pocket is configured so that an answer card can be inserted therein to show a series of answers frontwards, and a picture rearwards. The small pockets holding in use a plurality of question cards, their inner faces showing part of a larger picture, their outer faces showing a question. The question cards and answer card configured so that when all the question cards are inserted in the correct locations, the part pictures on their rear faces will mosaic to show substantially the same picture as on the rear of the answer card.

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.